Stockholm Stock Exchange | Mid Cap
Calliditas
+41.30%
Latest
+41.30%
3 months
CarnegieCiti Investment ResearchKempenSEB EquitiesSEB

Price Targets

Latest price targets per analyst.

AnalystPrice TargetDateUpside
Carnegie130 SEKMay 20
+41.30%
Citi Investment Research768.16 SEKDec -21
Kempen320 SEKDec -21
SEB Equities75 SEKNov -21
SEB170 SEKJul -21

About The Company

Calliditas vision is to leverage its interdisciplinary expertise in pharmaceutical product development to identify, develop and commercialize novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Calliditas